Brokerages Anticipate REDHILL BIOPHAR/S (RDHL) Will Announce Earnings of -$0.40 Per Share

Share on StockTwits

Equities analysts expect that REDHILL BIOPHAR/S (NASDAQ:RDHL) will announce earnings of ($0.40) per share for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for REDHILL BIOPHAR/S’s earnings. The lowest EPS estimate is ($0.40) and the highest is ($0.39). REDHILL BIOPHAR/S posted earnings of ($0.90) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 55.6%. The firm is scheduled to announce its next earnings results on Monday, November 12th.

On average, analysts expect that REDHILL BIOPHAR/S will report full-year earnings of ($1.69) per share for the current financial year, with EPS estimates ranging from ($1.70) to ($1.67). For the next fiscal year, analysts forecast that the business will report earnings of ($1.34) per share, with EPS estimates ranging from ($1.80) to ($1.00). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for REDHILL BIOPHAR/S.

REDHILL BIOPHAR/S (NASDAQ:RDHL) last issued its quarterly earnings results on Thursday, August 30th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). The business had revenue of $2.35 million for the quarter, compared to analysts’ expectations of $2.77 million. REDHILL BIOPHAR/S had a negative return on equity of 133.07% and a negative net margin of 564.71%.

A number of equities analysts have issued reports on the company. ValuEngine upgraded REDHILL BIOPHAR/S from a “sell” rating to a “hold” rating in a research report on Friday, June 29th. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of REDHILL BIOPHAR/S in a research report on Monday, July 2nd. LADENBURG THALM/SH SH assumed coverage on REDHILL BIOPHAR/S in a research report on Monday, June 25th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Zacks Investment Research upgraded REDHILL BIOPHAR/S from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research report on Friday, October 5th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. REDHILL BIOPHAR/S currently has an average rating of “Buy” and an average price target of $20.80.

A hedge fund recently raised its stake in REDHILL BIOPHAR/S stock. ARK Investment Management LLC raised its position in shares of REDHILL BIOPHAR/S (NASDAQ:RDHL) by 8.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 112,648 shares of the biotechnology company’s stock after acquiring an additional 8,894 shares during the quarter. ARK Investment Management LLC owned approximately 0.53% of REDHILL BIOPHAR/S worth $961,000 as of its most recent SEC filing. Institutional investors own 22.50% of the company’s stock.

Shares of RDHL stock opened at $8.47 on Tuesday. The company has a market cap of $187.84 million, a price-to-earnings ratio of -3.16 and a beta of 0.74. REDHILL BIOPHAR/S has a 12-month low of $4.30 and a 12-month high of $11.49.

About REDHILL BIOPHAR/S

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs.

Featured Article: Stock Symbols, CUSIP and Other Stock Identifiers

Get a free copy of the Zacks research report on REDHILL BIOPHAR/S (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.